US Medicare Wastage ‘Refund’: Wasted Effort?
The upcoming implementation of a new ‘refund’ program for unused drugs included in single-use vials is a remarkable story of a policy idea moving from academic research into the real world. But the actual impact sure has shrunk along the way.
You may also be interested in...
Regulation from CMS may drive manufacturers to repackage Medicare Part B drugs sold in single-use containers to avoid waste that would be subject to new rebate.
Policymakers should instead focus on increasing efficiencies in drug development, distribution and reimbursement, National Academies report says, while also seeking broad policies like HHS direct negotiation for drug prices in Medicare.
Amgen, Takeda and Merck push back against article’s conclusions on the waste generated by current vials for infused drugs.